Latest News

 

Setmelanotide approved as treatment for genetic obesity syndromes

US FDA has approved Setmelanotide for patients with obesity due to POMC, PCSK1 or LEPR deficiency

Dale Medal 2021

Prof Sadaf Farooqi awarded the highest honour bestowed by the Society for Endocrinology

Phase 3 trial shows Setmelanotide leads to weight loss

With colleagues, we showed that Setmelanotide is effective in treating severe obesity caused by POMC or LEPR deficiency

 

 

 
 

Latest News See all news>>

Setmelanotide approved as treatment for genetic obesity syndromes

US FDA has approved Setmelanotide for patients with obesity due to POMC, PCSK1 or LEPR deficiency

Dale Medal 2021

Prof Sadaf Farooqi awarded the highest honour bestowed by the Society for Endocrinology

© Genetics of Obesity Study 2021 | Privacy Policy
Website by iDentityCreative